These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21717218)

  • 1. Deletion of chromosome 4q predicts outcome in stage II colon cancer patients.
    Brosens RP; Belt EJ; Haan JC; Buffart TE; Carvalho B; Grabsch H; Quirke P; Cuesta MA; Engel AF; Ylstra B; Meijer GA
    Cell Oncol (Dordr); 2011 Jun; 34(3):215-23. PubMed ID: 21717218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletion of chromosome 4q predicts outcome in stage II colon cancer patients.
    Brosens RP; Belt EJ; Haan JC; Buffart TE; Carvalho B; Grabsch H; Quirke P; Cuesta MA; Engel AF; Ylstra B; Meijer GA
    Anal Cell Pathol (Amst); 2010; 33(2):95-104. PubMed ID: 20966546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients.
    van den Broek E; Krijgsman O; Sie D; Tijssen M; Mongera S; van de Wiel MA; Belt EJ; den Uil SH; Bril H; Stockmann HB; Ylstra B; Carvalho B; Meijer GA; Fijneman RJ
    Oncotarget; 2016 Nov; 7(45):73876-73887. PubMed ID: 27729614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focus on 16p13.3 Locus in Colon Cancer.
    Mampaey E; Fieuw A; Van Laethem T; Ferdinande L; Claes K; Ceelen W; Van Nieuwenhove Y; Pattyn P; De Man M; De Ruyck K; Van Roy N; Geboes K; Laurent S
    PLoS One; 2015; 10(7):e0131421. PubMed ID: 26222184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1p36 deletion is a marker for tumour dissemination in microsatellite stable stage II-III colon cancer.
    Mayrhofer M; Kultima HG; Birgisson H; Sundström M; Mathot L; Edlund K; Viklund B; Sjöblom T; Botling J; Micke P; Påhlman L; Glimelius B; Isaksson A
    BMC Cancer; 2014 Nov; 14():872. PubMed ID: 25420937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell cycle proteins predict recurrence in stage II and III colon cancer.
    Belt EJ; Brosens RP; Delis-van Diemen PM; Bril H; Tijssen M; van Essen DF; Heymans MW; Beliën JA; Stockmann HB; Meijer S; Meijer GA
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S682-92. PubMed ID: 22311118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Copy number variations in DCC/18q and ERBB2/17q are associated with disease-free survival in microsatellite stable colon cancer.
    Sefrioui D; Vermeulin T; Blanchard F; Chapusot C; Beaussire L; Armengol-Debeir L; Sesboué R; Gangloff A; Hebbar M; Copin MC; Houivet E; Schwarz L; Clatot F; Tuech JJ; Bénichou J; Martin L; Bouvier AM; Sabourin JC; Sarafan-Vasseur N; Frébourg T; Lepage C; Michel P; Di Fiore F
    Int J Cancer; 2017 Apr; 140(7):1653-1661. PubMed ID: 28006840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic values of chromosome 18q microsatellite alterations in stage II colonic carcinoma.
    Wang W; Wang GQ; Sun XW; Chen G; Li YF; Zhang LY; Qiu HB; Huang CY; Zhan YQ; Zhou ZW
    World J Gastroenterol; 2010 Dec; 16(47):6026-34. PubMed ID: 21157981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
    Watanabe T; Wu TT; Catalano PJ; Ueki T; Satriano R; Haller DG; Benson AB; Hamilton SR
    N Engl J Med; 2001 Apr; 344(16):1196-206. PubMed ID: 11309634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candidate driver genes in focal chromosomal aberrations of stage II colon cancer.
    Brosens RP; Haan JC; Carvalho B; Rustenburg F; Grabsch H; Quirke P; Engel AF; Cuesta MA; Maughan N; Flens M; Meijer GA; Ylstra B
    J Pathol; 2010 Aug; 221(4):411-24. PubMed ID: 20593488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation analysis between loss of heterozygosity at chromosome 18q and prognosis in the stage-II colon cancer patients.
    Wang W; Li YF; Sun XW; Chen G; Zhan YQ; Huang CY; Wan DS; Pan ZZ; Zhou ZW
    Chin J Cancer; 2010 Aug; 29(8):761-7. PubMed ID: 20663324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer.
    de Weger VA; Turksma AW; Voorham QJ; Euler Z; Bril H; van den Eertwegh AJ; Bloemena E; Pinedo HM; Vermorken JB; van Tinteren H; Meijer GA; Hooijberg E
    Clin Cancer Res; 2012 Feb; 18(3):882-9. PubMed ID: 22156611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosomal instability in microsatellite-unstable and stable colon cancer.
    Trautmann K; Terdiman JP; French AJ; Roydasgupta R; Sein N; Kakar S; Fridlyand J; Snijders AM; Albertson DG; Thibodeau SN; Waldman FM
    Clin Cancer Res; 2006 Nov; 12(21):6379-85. PubMed ID: 17085649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
    Chouhan H; Sammour T; Thomas ML; Moore JW
    J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of lamin A/C expression in stage II and III colon cancer is associated with disease recurrence.
    Belt EJ; Fijneman RJ; van den Berg EG; Bril H; Delis-van Diemen PM; Tijssen M; van Essen HF; de Lange-de Klerk ES; Beliën JA; Stockmann HB; Meijer S; Meijer GA
    Eur J Cancer; 2011 Aug; 47(12):1837-45. PubMed ID: 21621406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copy-number intratumor heterogeneity increases the risk of relapse in chemotherapy-naive stage II colon cancer.
    Lahoz S; Archilla I; Asensio E; Hernández-Illán E; Ferrer Q; López-Prades S; Nadeu F; Del Rey J; Sanz-Pamplona R; Lozano JJ; Castells A; Cuatrecasas M; Camps J
    J Pathol; 2022 May; 257(1):68-81. PubMed ID: 35066875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
    Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
    Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
    Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
    J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer.
    Lanza G; Matteuzzi M; Gafá R; Orvieto E; Maestri I; Santini A; del Senno L
    Int J Cancer; 1998 Aug; 79(4):390-5. PubMed ID: 9699532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsatellite instability is associated with reduced disease specific survival in stage III colon cancer.
    Mohan HM; Ryan E; Balasubramanian I; Kennelly R; Geraghty R; Sclafani F; Fennelly D; McDermott R; Ryan EJ; O'Donoghue D; Hyland JM; Martin ST; O'Connell PR; Gibbons D; Winter D; Sheahan K
    Eur J Surg Oncol; 2016 Nov; 42(11):1680-1686. PubMed ID: 27370895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.